BackGroup home
Taichu Biotechnology
Innovative Drug Non Clinical Research and Service Platform (CRO)
AceMab
AceMouse ™- The most perfect antibody fully humanized mouse platform (CRO)
Tarlead
Antibody drug process development and production service platform (CDMO)
TJR BIO
End-to-end Service from Oligonucleotide R&D to drug product manufacturing (CDMO)
Taichu (Shenzhen)
Consulting Services&Business Activities
TJR BIO
End-to-end Service from Oligonucleotide R&D to drug product manufacturing (CDMO)
TJR BIO is committed to providing global clients with one-stop services from nucleic acid drug development to production. The company offers comprehensive solutions, including chemical modification of nucleic acids, development of conjugated drugs (such as AOC), process and analytical method development, active pharmaceutical ingredient (API) production, and LNP formulation development for nucleic acid drugs (e.g., small nucleic acids and mRNA).
Contact

Services & Solutions

  • Oligonucleotide Drugs Process Development
    ASO & siRNA: milligram to hectogram synthesis experience
    PMO: milligram to gram synthesis experience
    CpG: milligram to kilogram synthesis experience
    Oligonucleotide Drugs Synthesis Technique
    Liquid phase synthesis, biosynthesis, etc
  • Analytical
    Covers starting materials, in-process analysis, intermediates, APIs, etc
    Stability Study
    Experiment of influencing factors, acceleration stability, long-term stability, etc

Our Team

The R&D team is headed by experienced PhDs who have worked in the field of Oligonucleotide R&D for many years.
TJR Bio has a dedicated team of scientists with extensive experience and expertise to support Oligonucleotide solid-phase synthesis, conjugation technology, and CMC process development. They have demonstrated proficiency in successfully scaling up the production of oligonucleotide products from milligrams to kilograms.
Team members are all experienced, they have worked in the Oligonucleotide drugs CDMO industry over 10 years.
The production team has rich experience in the project from R&D to GMP production at the scale from grams to kilograms.

Facilities

The total area is 6,000 m².
This includes a CMC process development and pilot production area of 4,200+ m² and a formulation production area of 1,700+ m².
Meet the simultaneous development of 5 process routes
Non GMP and GMP production in grams and hundreds of grams
Three or more kilogram level GMP production lines
Establishment of Coupling Technology Platform
PMO R&D platform
A commercialized formulation production line
Company Dynamics
More